N Montagne

1.8k total citations · 1 hit paper
16 papers, 924 citations indexed

About

N Montagne is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, N Montagne has authored 16 papers receiving a total of 924 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Infectious Diseases, 7 papers in Virology and 3 papers in Epidemiology. Recurrent topics in N Montagne's work include HIV Research and Treatment (7 papers), HIV/AIDS Research and Interventions (5 papers) and HIV/AIDS drug development and treatment (5 papers). N Montagne is often cited by papers focused on HIV Research and Treatment (7 papers), HIV/AIDS Research and Interventions (5 papers) and HIV/AIDS drug development and treatment (5 papers). N Montagne collaborates with scholars based in France, Monaco and United States. N Montagne's co-authors include P. Dellamonica, J. Durant, Philippe Clevenbergh, Philippe Halfon, CAB Boucher, Pascal Del-Giudice, Pere Simonet, P. Del Giudice, Jonathan Schapiro and R. Garraffo and has published in prestigious journals such as The Lancet, Blood and AIDS.

In The Last Decade

N Montagne

15 papers receiving 883 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial

1999 559 citations J. Durant, Philippe Clevenbergh et al. The Lancet profile →

Peers

Countries citing papers authored by N Montagne

Since Specialization

Citations

This map shows the geographic impact of N Montagne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N Montagne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N Montagne more than expected).

Fields of papers citing papers by N Montagne

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N Montagne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N Montagne. The network helps show where N Montagne may publish in the future.

Co-authorship network of co-authors of N Montagne

This figure shows the co-authorship network connecting the top 25 collaborators of N Montagne. A scholar is included among the top collaborators of N Montagne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N Montagne. N Montagne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Procalcitonin and C-Reactive Protein/Procalcitonin Ratio as Markers of Infection in Patients With Solid Tumors 2021 ·Frontiers in Medicine ·Matteo Vassallo, (unknown), Roxane Fabre, (unknown), (unknown), Nicolas Weiss, (unknown), (unknown), (unknown), (unknown), (unknown), N Montagne	10
2	Evaluation of Three Brief Screening Tests for Older Patients with Mild HIVAssociated Neurocognitive Disorders in the cART Era 2017 ·Journal of Neurology & Neurophysiology ·Matteo Vassallo, (unknown), Roxane Fabre, (unknown), Christine Lebrun‐Frénay, (unknown), Brigitte Dunais, N Montagne, Christian Pradier	2
3	Short-course daptomycin lock and systemic therapy for catheter-related bloodstream infections: a retrospective cohort study in cancer patients with surgically implanted devices 2017 ·Journal of Chemotherapy ·Matteo Vassallo, (unknown), Brigitte Dunais, (unknown), (unknown), (unknown), (unknown), (unknown), Nicolas Weiss, (unknown), (unknown), Christophe Perrin, N Montagne	10
4	Virologically suppressed patients with asymptomatic and symptomatic HIV‐associated neurocognitive disorders do not display the same pattern of immune activation 2015 ·HIV Medicine ·Matteo Vassallo, J. Durant, Christine Lebrun‐Frénay, Roxane Fabre, Michel Ticchioni, Signe T. Andersen, (unknown), (unknown), Brigitte Dunais, Isabelle Cohen-Codar, N Montagne, Éric Cua, (unknown), (unknown), Jacqueline Cottalorda, P. Dellamonica, Christian Pradier	26
5	Visceral leishmaniasis due to Leishmania infantumwith renal involvement in HIV-infected patients 2014 ·BMC Infectious Diseases ·Matteo Vassallo, Olivier Moranne, Damien Ambrosetti, Pierre‐Yves Jeandel, Christelle Pomarès, Élisabeth Cassuto, (unknown), Guillaume Giraud, N Montagne, Chiara Dentone, (unknown), Barbara Villaggio, G Secondo, (unknown), (unknown), (unknown), (unknown), Pierre Marty, Éric Rosenthal	6
6	Total genomic alteration as measured by SNP-array-based molecular karyotyping is predictive of overall survival in a cohort of MDS or AML patients treated with azacitidine 2013 ·Blood Cancer Journal ·Thomas Cluzeau, Chimène Moreilhon, Nicolas Mounier, (unknown), Lauris Gastaud, (unknown), Daniele Lo Re, N Montagne, (unknown), Patrick Auberger, J.G. Fuzibet, J.P. Cassuto, Sophie Raynaud	14
7	Monosomal karyotype improves IPSS‐R stratification in MDS and AML patients treated with Azacitidine 2013 ·American Journal of Hematology ·Thomas Cluzeau, Nicolas Mounier, (unknown), Valentine Richez, Laurence Legros, Lauris Gastaud, Georges Garnier, Daniel Ré, N Montagne, (unknown), (unknown), Patrick Auberger, Sophie Raynaud, Jill‐Patrice Cassuto	12
8	Azacitidine Overcomes Prognosis Impact of Poor and Very Poor IPSS-Revised in RAEB-2 Patients but Not in AML Patients. 2012 ·Blood ·Thomas Cluzeau, Nicolas Mounier, Valentine Richez, (unknown), Faézeh Legrand, Lionel Mannone, H Vinti, Laurence Legros, Lauris Gastaud, A. Thyss, Georges Garnier, Daniel Ré, N Montagne, (unknown), Patrick Auberger, Sophie Raynaud, Jill‐Patrice Cassuto	1
9	Variable Virological Outcomes According to the Center Providing Antiretroviral Therapy Within the PharmAdapt Clinical Trial 2003 ·HIV Clinical Trials ·Philippe Clevenbergh, Marie‐Cécile Bozonnat, Myriam Kirstetter, J. Durant, Éric Cua, P. Del Giudice, N Montagne, Pere Simonet, P. Dellamonica, (unknown)	4
10	Neurocysticercose de diagnostic tardif : à propos de deux cas 2002 ·La Revue de Médecine Interne ·F. Vandenbos, (unknown), (unknown), (unknown), P. Paquis, M. Gari-Toussaint, Marie‐Christine Saint‐Paul, N Montagne	4
11	Long-Term Virological Outcome in Patients Infected with Multi-Nucleoside Analogue-Resistant HIV-1 2002 ·Antiviral Therapy ·Philippe Clevenbergh, Myriam Kirstetter, (unknown), M. Dupon, Patrick Philibert, Christine Jacomet, Éric Cua, N Montagne, (unknown), P. Dellamonica	2
12	[Endocarditis, meningitis, pneumopathy and pneumococcal cerebral abscess in an alcoholic smoker]. 2001 ·PubMed ·(unknown), (unknown), N Montagne	2
13	Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study 2000 ·AIDS ·J. Durant, Philippe Clevenbergh, R. Garraffo, Philippe Halfon, (unknown), P. Del Giudice, N Montagne, Jonathan Schapiro, P. Dellamonica	182
14	Persisting Long-Term Benefit of Genotype-Guided Treatment for HIV-Infected Patients Failing Haart. The Viradapt Study: Week 48 Follow-Up 2000 ·Antiviral Therapy ·Philippe Clevenbergh, J. Durant, Philippe Halfon, P. Del Giudice, V. Mondain, N Montagne, (unknown), CAB Boucher, P. Dellamonica	90
15	Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial breakdown → 1999 ·The Lancet ·J. Durant, Philippe Clevenbergh, Philippe Halfon, Pascal Del-Giudice, (unknown), Pere Simonet, N Montagne, CAB Boucher, (unknown), P. Dellamonica	559
16	[Non-traumatic rhabdomyolysis in Staphylococcus aureus septicemia]. 1988 ·PubMed ·B Taillan, H Vinti, J.G. Fuzibet, (unknown), N Montagne, P Dujardin	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact